PGN 0052
Alternative Names: PGN 52; PGN0052Latest Information Update: 13 Feb 2007
At a glance
- Originator Pharmagene
- Class Antiasthmatics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma; Chronic obstructive pulmonary disease; Cystic fibrosis
Most Recent Events
- 09 Nov 2005 Phase-II clinical trials in Cystic fibrosis in United Kingdom (IV-infusion)
- 26 May 2005 Suspended - Preclinical for Asthma in United Kingdom (IV)
- 26 May 2005 Suspended - Preclinical for Chronic obstructive pulmonary disease in United Kingdom (IV)